Report : Europe Peripheral Vascular Devices Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Peripheral Vascular Stents, Peripheral Transluminal Angioplasty Balloon Catheters, PTA Guidewires, Atherectomy Devices, Chronic Total Occlusion Devices, Aortic Stents, Synthetic Surgical Grafts, and Embolization Guidewires) and End User (Hospitals & Clinics, Ambulatory Care Centers, Specialty Clinics, and Others)
At 6.3% CAGR, the Europe Peripheral Vascular Devices Market is speculated to be worth US$ 5,035.19 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the Europe peripheral vascular devices market was valued at US$ 3,288.55 million in 2021 and is expected to reach US$ 5,035.19 million by 2028, registering an annual growth rate of 6.3% from 2021 to 2028. Increasing prevalence of peripheral artery disease and arterial embolism and rising incidences of atherosclerosis, smoking, alcoholism, and obesity and arterial embolism are the critical factors attributed to the market expansion.
The three most common CVDs across the region are coronary heart disease, cerebrovascular disease, and peripheral artery disease. Although cardiovascular disease prevention and control has gained traction in recent decades, efforts have primarily focused on coronary heart disease and cerebrovascular disease, the world's leading causes of mortality. Despite receiving less attention, peripheral artery disease has emerged as a significant contributor to the worldwide deaths and disabilities, with an increasing burden in low-income and middle-income countries (LMICs). A blockage in the blood vessels causes peripheral arterial disease (PAD) or peripheral vascular disease (PVD), which reduces blood flow to the limbs, most commonly the legs. An arterial embolism occurs when a mass of tissue or a foreign substance moves through the vascular tree and lodges in a distant artery, blocking blood flow. Ischemia, organ failure, and possible infarction result from this blockage. Medical and surgical emergencies, such as stroke, acute limb ischemia, mesenteric ischemia, and renal failure, are symptoms of this complex condition. Due to pre-existing factors, such as age, hypercoagulability, cardiac abnormalities, and atherosclerotic disease, surgical and intensive care patients are at a higher risk for arterial embolization. These factors are supporting the peripheral vascular devices market substantially across the region.
On the contrary, high costs and complications associated with embolization procedures hurdles the growth of Europe peripheral vascular devices market.
Based on product, the Europe peripheral vascular devices market is segmented into peripheral vascular stents, peripheral transluminal angioplasty balloon catheters, PTA guidewires, atherectomy devices, chronic total occlusion devices, aortic stents, synthetic surgical grafts, and embolization guidewires. The peripheral vascular stents segment held 34.0% market share in 2021, amassing US$ 1,117.97 million. It is projected to garner US$ 1,797.45 million by 2028 to expand at 7.0% CAGR during 2021–2028.
Based on end user, the Europe peripheral vascular devices market is segmented into hospitals & clinics, ambulatory care centers, specialty clinics, and others. The hospitals & clinics segment held 38.8% market share in 2021, amassing US$ 1,276.08 million. It is projected to garner US$ 2,002.29 million by 2028 to expand at 6.6% CAGR during 2021–2028.
Based on country, the Europe peripheral vascular devices market is segmented into the France, Germany, France, UK, Italy, Spain, and Rest of Europe. Our regional analysis states that the Germany captured 21.7% market share in 2021. It was assessed at US$ 714.60 million in 2021 and is likely to hit US$ 969.27 million by 2028, exhibiting a CAGR of 6.0% during the forecast period.
Key players dominating the Europe peripheral vascular devices market are Abbott, B. Braun Melsungen AG, BD, Boston Scientific Corporation, Cardinal Health Inc, Cook Medical LLC, Edwards Lifesciences Corporation, Medtronic, Teleflex Incorporated, and Terumo Corporation among others.
- In Sep 2021, Abbott acquired Walk Vascular, LLC to expand peripheral vascular offerings, and incorporate into Abbott's existing endovascular product portfolio. Financial terms of the acquisition were not disclosed by the companies.
- In Nov 2020, Cook Medical LLC announced that Zilver Vena venous self-expanding stent is commercially accessible to physicians in the United States for the treatment of symptomatic iliofemoral venous outflow obstruction.
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email Id: firstname.lastname@example.org